Head-To-Head Review: Scilex (NASDAQ:SCLX) & Cumberland Pharmaceuticals (NASDAQ:CPIX)

Scilex (NASDAQ:SCLX – Get Free Report) and Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Insider and Institutional Ownership

69.7% of Scilex shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 4.5% of Scilex shares are held by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Scilex and Cumberland Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Scilex -1,414.57% N/A -147.00%
Cumberland Pharmaceuticals 274.38% -31.40% -9.38%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Scilex and Cumberland Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scilex 1 0 0 0 1.00
Cumberland Pharmaceuticals 1 0 0 0 1.00

Volatility and Risk

Scilex has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500.

Earnings and Valuation

This table compares Scilex and Cumberland Pharmaceuticals”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Scilex $30.25 million 0.40 -$358.73 million ($49.70) -0.03
Cumberland Pharmaceuticals $44.52 million 1.98 -$2.84 million $4.49 1.31

Cumberland Pharmaceuticals has higher revenue and earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Cumberland Pharmaceuticals beats Scilex on 8 of the 11 factors compared between the two stocks.

About Scilex

(Get Free Report)

Scilex Holding Company is a biopharmaceutical company focused on developing and commercializing treatments for pain and related conditions. Its portfolio includes therapies designed to offer alternatives to conventional pain-management approaches. Its marketed products include ZTlido, a topical lidocaine system for pain associated with postherpetic neuralgia; Elyxyb, an oral celecoxib solution for acute migraine in adults; and GLOPERBA, an oral colchicine solution for preventing gout flares in adults.

About Cumberland Pharmaceuticals

(Get Free Report)

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company based in Nashville, Tennessee. Founded in 1999, the company develops, acquires and commercializes branded prescription medicines, with a focus on products used in hospital and other acute-care settings as well as treatments for chronic conditions. Its marketed products include Acetadote, an intravenous treatment for acetaminophen overdose; Caldolor, an intravenous ibuprofen product used to treat pain and fever; and Kristalose, a prescription treatment for constipation.

Receive News & Ratings for Scilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scilex and related companies with MarketBeat.com's FREE daily email newsletter.